Product Description
OPN-6602 is a potent and selective EP300/CBP bromodomain inhibitor. OPN-6602 blocks signaling involved in cell growth and tumorigenesis by modulation of histone acetylation and the recruitment of EP300/CBP bromodomains. OPN-6602 reduces androgen receptor (AR)-driven and MYC gene expression while acting through a distinct mechanism from BET bromodomain inhibitors. Inhibition of AR signaling with OPN-6602 has been shown to reduce tumor growth in metastatic castration resistant prostate cancer (mCRPC) xenograft and PDX models. (Sourced from: https://www.opnabio.com/programs/opn-6602/)
Mechanisms of Action: p300/CBP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Opna Bio
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| OPN6602-C01 | P1 |
Recruiting |
Multiple Myeloma |
2026-07-01 |